Autoimmune Drug Reactions To Get Further FDA Research After Ziagen Side Effect Findings
This article was originally published in The Pink Sheet Daily
Executive Summary
Carriers of the HLAB*57:01 allele who take Ziagen can come down with severe autoimmune reactions due to a mechanism traced by agency researchers.
You may also be interested in...
Targeted Therapies Have Most Clinically Useful Biomarker Labeling
Pharmacogenetic biomarkers for molecularly targeted therapies are supported by considerably better evidence that they improve patient outcomes than biomarkers in labeling of untargeted drugs, but a JAMA study still found that half of biomarkers in label lacked convincing evidence of clinical utility.
GSK’s Ziagen Relabeled: REMS And The Path To Personalized Medicine
A relabeling of GlaxoSmithKline's HIV treatment Ziagen (abacavir sulfate) to recommend pharmacogenomic screening illustrates the potential for FDA's new drug safety tools to encourage the push towards personalized medicine
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.